Scinai Immunotherapeutics Ltd ADR (NASDAQ:SCNI)’s traded shares stood at 73299.0 during the last session, with the company’s beta value hitting 1.88. At the close of trading, the stock’s price was $2.2, to imply a decrease of -2.95% or -$0.07 in intraday trading. The SCNI share’s 52-week high remains $8.92, putting it -305.45% down since that peak but still an impressive 13.64% since price per share fell to its 52-week low of $1.90. The company has a valuation of $1.87M, with an average of 0.12 million shares in intraday trading volume over the past 10 days and average of 379.98K shares over the past 3 months.
Scinai Immunotherapeutics Ltd ADR (NASDAQ:SCNI) trade information
After registering a -2.95% downside in the last session, Scinai Immunotherapeutics Ltd ADR (SCNI) has traded red over the past five days. The 5-day price performance for the stock is -10.81%, and -7.82% over 30 days. With these gigs, the year-to-date price performance is -25.07%. Short interest in Scinai Immunotherapeutics Ltd ADR (NASDAQ:SCNI) saw shorts transact 41266.0 shares and set a 0.04 days time to cover.
SCNI Dividends
Scinai Immunotherapeutics Ltd ADR has its next earnings report out on 2024-May-15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Scinai Immunotherapeutics Ltd ADR (NASDAQ:SCNI)’s Major holders
Scinai Immunotherapeutics Ltd ADR insiders hold 18.22% of total outstanding shares, with institutional holders owning 26.55% of the shares at 32.46% float percentage. In total, 26.55% institutions holds shares in the company, led by MORGAN STANLEY.